Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) major shareholder Jorey Chernett sold 86,757 shares of the business’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $1.61, for a total value of $139,678.77. Following the completion of the sale, the insider directly owned 10,219,468 shares of the company’s stock, valued at approximately $16,453,343.48. This trade represents a 0.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Jorey Chernett also recently made the following trade(s):
- On Friday, November 6th, Jorey Chernett sold 250,804 shares of Neuronetics stock. The stock was sold at an average price of $2.39, for a total transaction of $599,421.56.
- On Friday, November 13th, Jorey Chernett sold 2,187,051 shares of Neuronetics stock. The shares were sold at an average price of $1.15, for a total value of $2,515,108.65.
- On Thursday, November 12th, Jorey Chernett sold 706,840 shares of Neuronetics stock. The shares were sold at an average price of $1.43, for a total value of $1,010,781.20.
- On Monday, November 9th, Jorey Chernett sold 103,959 shares of Neuronetics stock. The shares were sold at an average price of $2.06, for a total transaction of $214,155.54.
- On Monday, November 9th, Jorey Chernett purchased 40,000 shares of Neuronetics stock. The stock was bought at an average cost of $1.99 per share, with a total value of $79,600.00.
- On Friday, October 30th, Jorey Chernett bought 18,000 shares of Neuronetics stock. The stock was purchased at an average cost of $2.27 per share, with a total value of $40,860.00.
Neuronetics Stock Performance
Shares of Neuronetics stock opened at $1.39 on Monday. Neuronetics, Inc. has a 12 month low of $0.80 and a 12 month high of $3.44. The company has a current ratio of 2.01, a quick ratio of 1.82 and a debt-to-equity ratio of 2.76. The business has a fifty day simple moving average of $2.35 and a two-hundred day simple moving average of $1.87. The firm has a market capitalization of $108.04 million, a P/E ratio of -4.21 and a beta of 1.36.
Neuronetics (NASDAQ:STIM – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.07. The business had revenue of $41.96 million for the quarter, compared to analysts’ expectations of $40.42 million. Neuronetics had a negative net margin of 14.45% and a negative return on equity of 102.23%. On average, equities analysts forecast that Neuronetics, Inc. will post -0.30 earnings per share for the current fiscal year.
Trending Headlines about Neuronetics
Here are a few of the latest headlines about STIM:
- Positive Sentiment: Third-quarter revenue was $41.96 million, above the $40.43 million analyst estimate, while its $0.02-per-share loss was narrower than the expected $0.09 loss. The results may support sentiment about improving performance. Article: Neuronetics stock: Q3 revenue rises as loss narrows
- Negative Sentiment: Major shareholder Jorey Chernett disclosed several sales from November 6–13, totaling about 3.34 million shares, partly offset by a 40,000-share purchase. After the latest sale, Chernett held about 7.33 million shares. The scale of the selling may raise concerns about near-term supply and investor confidence. SEC filing on Chernett’s transactions
Hedge Funds Weigh In On Neuronetics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Madryn Asset Management LP bought a new stake in Neuronetics during the 2nd quarter worth approximately $24,102,634. Marshall Wace LLP lifted its stake in shares of Neuronetics by 219.5% during the 3rd quarter. Marshall Wace LLP now owns 1,551,840 shares of the company’s stock valued at $3,631,000 after buying an additional 1,066,148 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Neuronetics by 95.4% in the 3rd quarter. HighTower Advisors LLC now owns 1,101,502 shares of the company’s stock worth $2,578,000 after buying an additional 537,761 shares during the period. FourWorld Capital Management LLC increased its stake in Neuronetics by 59.9% in the 1st quarter. FourWorld Capital Management LLC now owns 1,489,322 shares of the company’s stock worth $2,160,000 after buying an additional 558,072 shares in the last quarter. Finally, BlackRock Inc. purchased a new position in shares of Neuronetics in the second quarter valued at about $776,000. 53.59% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on STIM. Citigroup reaffirmed a “market outperform” rating on shares of Neuronetics in a research report on Tuesday, July 21st. BTIG Research reiterated a “buy” rating and issued a $6.00 price target on shares of Neuronetics in a research note on Thursday, September 17th. B. Riley Financial raised their target price on shares of Neuronetics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Neuronetics in a research note on Monday, September 14th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $5.00.
Check Out Our Latest Report on Neuronetics
About Neuronetics
Neuronetics, Inc. is a medical technology company that develops and commercializes noninvasive treatments for certain mental health conditions. Its flagship product is the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain. NeuroStar is FDA-cleared for treating major depressive disorder in adults who have not achieved satisfactory improvement with antidepressant medication. The company also provides treatment-related services and support for clinicians and patients.
Featured Articles
- Five stocks we like better than Neuronetics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.
